Bob Iaccino, chief market strategist at Tethys Partners, says that U.S. groups' guidance has been on the negative side and discusses what will drive the market this week.» Read More
The electric car championship has secured funding and TV deals across the world ahead of its first season, says Alejandro Agag, CEO of Formula E Holdings.
Kiran Kowshik, currency strategist at BNP Paribas, discusses the U.K. economy following the release of the latest unemployment data.
Pelham Smithers, head of Asian research at Pelham Smithers Associates, says Sony will remain in trouble until it can work out a way to "create an environment" to make its hardware electronics profitable.
CNBC's Catherine Boyle comments on the latest developments in the GSK bribery investigation in China and on the second day of hearings for Pfizer and AstraZeneca's CEOs.
Pascal Soriot, AstraZeneca CEO, says the group has what it takes to succeed on its own and that its "stand-alone strategy" will create value for its shareholders.
AstraZeneca has the "critical mass" to succeed internationally, Pascal Soriot, CEO of AstraZeneca told CNBC, also discussing the group¿s pipeline.
Jason Kolbert, head of health care equity research at Maxim Group, says Pfizer's takeover bid is driven by AstraZeneca's pipeline, strategic tax advantages and cost savings.
Ian Read, CEO of Pfizer, says there is a "very strong industrial rationale" behind its AstraZeneca's takeover bid, as the groups' pipelines would both benefit from being combined.
Andrew Burkly, head of institutional portfolio strategy at Oppenheimer & Co., says the underlying fundamentals for U.S. equities remain "pretty constructive", and large cap stocks should outperform small caps this year.
Gerhard Roiss, CEO of OMV, discusses the impact of the Russian sanctions on European gas, and dismisses calls for a unified gas price across the region.
Scott Moeller, director of the M&A research centre at Cass Business School, discusses the potential AstraZeneca takeover and Pfizer's strategy.
Nicolas De Santis, president and secretary general at Gold Mercury International, says the European Union has an "identity problem" and needs a stronger brand and identity.
Christian Keller, head of emerging markets research at Barclays, says emerging market credit valuation is quite attractive but advises being "choosy and picky."
Chuka Umunna, U.K. shadow business secretary, says the potential AstraZeneca takeover by Pfizer should be looked at as of national economic interest, and that more should be done to protect R&D jobs.
Ranjith Gopinathan, program manager for life sciences and health care practice at Frost & Sullivan, explains why he believes the Pfizer/AstraZeneca deal would be positive.
Mebane Faber, CIO of Cambria Investment Management, discusses where to get the best-value equities now there are a lot of "very cheap" countries.
The European Union will not recognize the "pseudo-referendum" in eastern Ukraine says Radoslaw Sikorski, Polish foreign minister, adding that it also refuses to recognize the annexation of Crimea.
Pfizer is "back on the attack" and trying to make sure the takeover of AstraZeneca is seen as being "all about science and medicine", CNBC's Catherine Boyle reports.
Michael O'Sullivan, CIO for U.K. and EMEA at Credit Suisse Private Bank, discusses M&A activity and says it's now "running into reality" as governments, shareholders and investors are becoming more vocal.
Atul Goyal, senior analyst at Jefferies, says Sharp is facing intensifying competition, warning that the group will need to raise "a lot of equity" in the coming year.